SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2017 / Cilt: 47 - Sayı: 2

Association of B7-H4 gene polymorphisms in urothelial bladder cancer

Asuman ÖZGÖZ
Ümit İNCE
Deniz DİNÇEL
Ahmet ŞAHİN
Hale ŞAMLI
Faruk BALCI
Yeşim SAĞLICAN
Murat ŞAMLI
Pages
443–446
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We conclude that B7-H4 has the potential to be a useful prognostic marker in urothelial carcinoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: We aimed to study polymorphisms of the B7-H4 gene in order to evaluate a possible association in urothelial carcinoma, as it is highly expressed in cancer tissues.
📊
Key Findings & Data:Materials and methods: In this study B7-H4 gene rs10754339, rs10801935, and rs3738414 SNPs were studied by PCR-RFLP method in paraffin-embedded tumor specimens from 62 urothelial carcinoma patients and in a control group including 30 patients without bladder cancer.
💡
Conclusion & Impact:We conclude that B7-H4 has the potential to be a useful prognostic marker in urothelial carcinoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: We aimed to study polymorphisms of the B7-H4 gene in order to evaluate a possible association in urothelial carcinoma, as it is highly expressed in cancer tissues. Materials and methods: In this study B7-H4 gene rs10754339, rs10801935, and rs3738414 SNPs were studied by PCR-RFLP method in paraffin-embedded tumor specimens from 62 urothelial carcinoma patients and in a control group including 30 patients without bladder cancer. Results: We detected that the rs10754339 polymorphism was more frequent in the cancer patients when compared with the control group (P < 0.05). Only the rs3738414 polymorphism showed a statistically significant difference in frequency between pathologic diagnostic groups. Conclusion: The rs10754339 AA genotype distribution was found to have a higher frequency whereas the rs3738414 AG genotype distribution was lower in the bladder cancer group (P < 0.05). None of the genotype distributions showed a significant difference from the control group for the rs10801935 polymorphism. We conclude that B7-H4 has the potential to be a useful prognostic marker in urothelial carcinoma.

🔖

Cite This Article

ÖZGÖZ, A., İNCE, Ü., DİNÇEL, D., ŞAHİN, A., ŞAMLI, H., BALCI, F., SAĞLICAN, Y., ŞAMLI, M. (2022). Association of B7-H4 gene polymorphisms in urothelial bladder cancer. Turkish Journal of Medical Sciences, Cilt: 47 - Sayı: 2, 443–446. https://ajindex.com/articles/610500

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Babaian AIu, Kariakin OB, Teplov AA, Zaletaev DV, Nemtsova MV. Some molecular-genetic markers, defining the pathogenesis of superficial and invasive bladder cancer. Mol Biol (Mosk) 2011; 45: 1012-1016
  2. Balbás-Martínez C, Rodríguez-Pinilla M, Casanova A, Domínguez O, Pisano DG, Gómez G, Lloreta J, Lorente JA, Malats N, Real FX. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS One 2013; 8: e62483
  3. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849-861
  4. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20: 29-53
  5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
  6. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007; 30: 251-260
  7. Martin-Orozco N, Dong C. Inhibitory costimulation and antitumor immunity. Semin Cancer Biol 2007; 17: 288-298
  8. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347
  9. Sharpe AH, Freeman GJ. The B7–CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126
  10. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477
  11. Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 2009; 19: 1481-1486
  12. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. P Natl Acad Sci USA 2003; 100: 10388-10392
  13. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. P Natl Acad Sci USA 2007; 104: 19458-19463
  14. Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K, Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 2003; 171: 4650-4654
  15. Quandt D, Fiedler E, Boettcher D, Marsch WCh, Seliger B. B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune r